Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MBRPM
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NV103
|
|||||
| Synonyms |
AntiCD99 TNS (CD99TNS/Ir); CD99/Irinotecan nanoparticles; Antibody-conjugated irinotecan liposomal nanoparticle (NanoValent Pharmaceuticals); NV 103; NV-103
Click to Show/Hide
|
|||||
| Organization |
NanoValent Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 3 Indication(s)
Ewing sarcoma [ICD11:2B52]
Clinical candidate
Glioblastoma [ICD11:2A00]
Clinical candidate
Neuroendocrine neoplasms [ICD11:2D4Y]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
CD99 antigen (CD99)
|
Antigen Info | ||||
| Payload Name |
Irinotecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.